PMID- 38377851
OWN - NLM
STAT- MEDLINE
DCOM- 20240325
LR  - 20240325
IS  - 1878-1705 (Electronic)
IS  - 1567-5769 (Linking)
VI  - 130
DP  - 2024 Mar 30
TI  - Pre-administration of human umbilical cord mesenchymal stem cells has better 
      therapeutic efficacy in rats with D-galactosamine-induced acute liver failure.
PG  - 111672
LID - S1567-5769(24)00190-5 [pii]
LID - 10.1016/j.intimp.2024.111672 [doi]
AB  - BACKGROUND: Acute liver failure (ALF) is characterized by an intense systemic 
      inflammatory response, single or multiple organ system failure and high 
      mortality. However, specific and effective treatments for ALF patients are still 
      lacking. According to the current investigation, human umbilical cord mesenchymal 
      stem cells (hUCMSCs) have shown remarkable potential to enhance the functional 
      recovery of injured livers. We aimed to investigate the therapeutic effects of 
      time-differentiated hUCMSCs administration regimens on ALF. METHODS: The rat 
      model of ALF was induced by D-galactosamine (D-gal), and hUCMSCs were 
      administered via the tail vein 12 h before or 2 h after induction. The potential 
      mechanisms of hUCMSCs in treatment of ALF, regulation cell subset and secretion 
      of inflammatory factors, were verified by co-culturing with PBMCs in vitro. Liver 
      function indicators were detected by an automatic biochemistry analyzer and 
      inflammatory factors were obtained by ELISA detection. The distribution of 
      hUCMSCs in rats after administration was followed by quantitative real-time 
      fluorescence PCR. RESULTS: The findings of the study discovered that 
      administration of hUCMSCs 12 h prior to surgery could significantly improve the 
      survival rate of rats, stabilize various liver function indicators in serum 
      levels of ALT, AST, T-BIL, or ALB diminish inflammatory infiltration in liver 
      tissue, and inhibit the secretion of inflammatory factors. CONCLUSION: Our data 
      showed that pre-transplantation of hUCMSCs had a better therapeutic effect on ALF 
      rats, providing empirical evidence for preclinical studies. Thus, the timing of 
      hUCMSCs transplantation is necessary for the optimal clinical treatment effect.
CI  - Copyright (c) 2024. Published by Elsevier B.V.
FAU - Li, Min
AU  - Li M
AD  - Sinoneural Cell Engineering Group Holdings., Co, Ltd, No.1188, Lianhang Road, 
      Shanghai 201100, PR China.
FAU - Zhang, Jigang
AU  - Zhang J
AD  - Clinical Research Center, Shanghai General Hospital, Shanghai Jiao Tong 
      University School of Medicine, No.100 Haining Road, Shanghai 200080, PR China; 
      Shanghai Engineering Research Center of Translational Medicine of Cell Therapy, 
      Shanghai 200080, PR China.
FAU - Fang, Jingmeng
AU  - Fang J
AD  - Sinoneural Cell Engineering Group Holdings., Co, Ltd, No.1188, Lianhang Road, 
      Shanghai 201100, PR China.
FAU - Xin, Yuan
AU  - Xin Y
AD  - Sinoneural Cell Engineering Group Holdings., Co, Ltd, No.1188, Lianhang Road, 
      Shanghai 201100, PR China.
FAU - Zhu, Hao
AU  - Zhu H
AD  - Sinoneural Cell Engineering Group Holdings., Co, Ltd, No.1188, Lianhang Road, 
      Shanghai 201100, PR China. Electronic address: zhuhao@sinoneural.com.
FAU - Ding, Xueying
AU  - Ding X
AD  - Clinical Research Center, Shanghai General Hospital, Shanghai Jiao Tong 
      University School of Medicine, No.100 Haining Road, Shanghai 200080, PR China; 
      Shanghai Engineering Research Center of Translational Medicine of Cell Therapy, 
      Shanghai 200080, PR China. Electronic address: dingxueying@126.com.
LA  - eng
PT  - Journal Article
DEP - 20240220
PL  - Netherlands
TA  - Int Immunopharmacol
JT  - International immunopharmacology
JID - 100965259
RN  - 7535-00-4 (Galactosamine)
SB  - IM
MH  - Humans
MH  - Rats
MH  - Animals
MH  - Galactosamine
MH  - *Liver Failure, Acute/therapy/surgery
MH  - *Mesenchymal Stem Cells
MH  - Umbilical Cord
MH  - *Mesenchymal Stem Cell Transplantation
OTO - NOTNLM
OT  - ALF
OT  - HUCMSCs
OT  - Inflammation
OT  - Liver function
OT  - Pre-transplantation
COIS- Declaration of competing interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2024/02/21 11:14
MHDA- 2024/03/25 06:43
CRDT- 2024/02/20 18:12
PHST- 2024/01/13 00:00 [received]
PHST- 2024/02/05 00:00 [revised]
PHST- 2024/02/07 00:00 [accepted]
PHST- 2024/03/25 06:43 [medline]
PHST- 2024/02/21 11:14 [pubmed]
PHST- 2024/02/20 18:12 [entrez]
AID - S1567-5769(24)00190-5 [pii]
AID - 10.1016/j.intimp.2024.111672 [doi]
PST - ppublish
SO  - Int Immunopharmacol. 2024 Mar 30;130:111672. doi: 10.1016/j.intimp.2024.111672. 
      Epub 2024 Feb 20.